An investor asked a question on the investor interaction platform: Hello, Secretary! You repeatedly replied to investors on the interactive basis: the company will continue to push ahead with the two core strategies: the promotion of the new diabetes care and care model “O+O” in China and the United States and the continuous introduction of the best price performance products in the new retail platform. Excuse me: what is the next product after the test box when you say that the popular products with the highest cost performance are continuously launched? Where is the product development now? If you can’t explain clearly, can you understand that the so-called core strategy you replied to is only written?
Andon Health Co.Ltd(002432) (002432. SZ) said on the investor interaction platform on January 25 that the company’s forehead thermometer products and the current covid-19 antigen kit products are the concentrated embodiment of the strategy of popular products. In the future, the company will continuously enrich the categories of popular products in combination with market demand.
